Application 761210

Type
BLA
Sponsor
JANSSEN BIOTECH

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001RYBREVANTAMIVANTAMAB-VMJWINJECTABLE;INJECTION350MG/7ML(50MG/ML)NoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
57894-501RybrevantAmivantamabJanssen Biotech, Inc.BLACurrent
57894-501RybrevantAmivantamabJanssen Biotech, Inc.BLACurrent
57894-501RybrevantAmivantamabJanssen Biotech, Inc.BLACurrent
57894-501RybrevantAmivantamabJanssen Biotech, Inc.BLACurrent
57894-501RybrevantAmivantamabJanssen Biotech, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
84139SUPPL 2025-11-12
84131SUPPL 2025-11-10
83708SUPPL 2025-10-09
83704SUPPL 2025-10-09
83381SUPPL 2025-09-18
83380SUPPL 2025-09-18
83110SUPPL 2025-08-18
83105SUPPL 2025-08-15
81270SUPPL 2025-02-18
81264SUPPL 2025-02-18
79673SUPPL 2024-09-20
79670SUPPL 2024-09-20
79459SUPPL 2024-08-22
79451SUPPL 2024-08-20
77705SUPPL 2024-03-04
77690SUPPL 2024-03-01
72577SUPPL2022-11-07
72569SUPPL2022-11-07
69752SUPPL2021-12-23
69743SUPPL2021-12-22
67867ORIG2021-06-23
67583ORIG2021-05-24
67572ORIG2021-05-21